Highlights of This Issue 3717

SPECIAL FEATURES

CCR Translations

3719 Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks
John M.L. Ebos and Roberto Pili
See article p. 3961

CCR Perspectives in Drug Approval

3722 Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

Molecular Pathways

3743 Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations
Jeyanthi Eswaran, Da-Qiang Li, Anil Shah, and Rakesh Kumar

Review

3750 Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
Victor Moreno Garcia, Briti Basu, L. Rhoda Molife, and Stan B. Kaye

HUMAN CANCER BIOLOGY

3762 Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact
Mário Henrique M. Barros, Rocio Hassan, and Gerald Niedobitek

3772 Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma
Yu Sawada, Motonobu Nakamura, Rieko Kabashima-Kubo, Takatoshi Shimauchi, Miwa Kobayashi, and Yoshiki Tokura

3780 FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma
Lisa E.S. Crose, Katherine T. Etheridge, Candy Chen, Brian Belyea, Lindsay J. Talbot, Rex C. Bentley, and Corinne M. Linardic

3791 Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia
Jennifer R. Brown, Megan Hanna, Bethany Tesar, Lillian Werner, Nathalie Pochet, John M. Asara, Yaoyu E. Wang, Paolo dal Cin, Stacey M. Fernandes, Christina Thompson, Laura MacConaill, Catherine J. Wu, Yves Van de Peer, Mick Correll, Aviv Regev, Donna Neuberg, and Arnold S. Freedman

Statistics in Clinical Cancer Research

3731 Cure Models as a Useful Statistical Tool for Analyzing Survival
Megan Othus, Bart Barlogie, Michael L. LeBlanc, and John J. Crowley

CCR Drug Updates

3737 Crizotinib for ALK-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target
Leena Gandhi and Pasi A. Jänne

The Journal of Clinical and Translational Research www.aacrjournals.org
CANCER THERAPY: PRECLINICAL

Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
Luigi Scotto, Marianna Krutlof-de Julio, Luca Paoluzzi, Matko Kalac, Enrica Marchi, Jaiso Baquero Buitrago, Jennifer Amengual, Michael M. Shen, and Owen A. O'Connor

Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia
Laura A. Vitale, Li-Zhen He, Lawrence J. Thomas, Jennifer Widger, Jeffrey Weidlick, Andrea Crocker, Thomas O’Neill, James Storey, Martin J. Glennie, Deanna M. Grote, Stephen M. Ansell, Henry Marsh, and Tibor Keler

Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy
Clare McCourt, Pamela Maxwell, Roberta Mazzucchelli, Rodolfo Montironi, Marina Scarpelli, Manuel Salto-Tellez, Joe M. O’Sullivan, Daniel B. Longley, and David J.J. Waugh

Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response
Harvey Wong, Edna F. Choo, Bruno Aliche, Xiao Ding, Hank La, Erin McNamara, Frank-Peter Theil, Jay Tibbitts, Lori S. Friedman, Cornelis E.C.A. Hop, and Stephen E. Gould

Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206
Eric Sanchez, Mingjie Li, Cathy Wang, Cydney M. Nichols, Jennifer Li, Haining Chen, and James R. Berenson

Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer
Mario Roselli, Romaine I. Fernando, Fiorella Guadagni, Antonella Spilia, Jhessica Alessandroni, Raffaela Palmirotta, Leopoldo Costarelli, Mary Litzinger, Duane Hamilton, Bruce Huang, Joanne Tucker, Kwong Yoc Tsang, Jeffrey Schom, and Claudia Palena

Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression
Shu Feng, Longjiang Shao, Wendong Yu, Paul Gavine, and Michael Ittmann

Resistance to TRAIL Is Mediated by DARPP-32 in Gastric Cancer
Abbes Belkhir, Shoumin Zhu, Zheng Chen, Mohammed Soutto, and Wael El-Rifai

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, and Deepak Sampath

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice
Kinya Inoue, Takuji Torimura, Toru Nakamura, Hideki Iwamoto, Hiroshi Masuda, Mitsuhiko Abe, Osamu Hashimoto, Hiromori Koga, Takato Ueno, Hirohisa Yano, and Michio Sata
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>3934</td>
<td>Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma</td>
<td>Jordan Madic, Sophie Piperno-Neumann, Vincent Servois, Aurore Rampanou, Maud Milder, Bénédicte Trouiller, David Gentien, Stéphanie Saada, Franck Assayag, Aurélie Thuleau, Fariba Nennati, Didier Decaudin, François-Clément Biedar, Laurence Desjardins, Pascale Mariani, Olivier Lantz, and Marc-Henri Stern</td>
<td>3972</td>
</tr>
<tr>
<td>3942</td>
<td>A Replication Study and Genome-Wide Scan of Single-Nucleotide Polymorphisms Associated with Pancreatic Cancer Risk and Overall Survival</td>
<td>Jason A. Willis, Sara H. Olson, Irene Orlow, Semanti Mukherjee, Robert R. McWilliams, Robert C. Kurtz, and Robert J. Klein</td>
<td>3982</td>
</tr>
<tr>
<td></td>
<td>See commentary p. 3719</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**IMAGING, DIAGNOSIS, PROGNOSIS**

**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

**CANCER THERAPY: CLINICAL**

**CORRECTION**

**Correction: A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck**
The inhibition of androgen signaling is a major therapeutic strategy in prostate cancer; however, response is often transient, and patients ultimately relapse on therapy giving rise to a currently incurable condition known as castrate-resistant prostate cancer (CRPC). McCourt and colleagues show elevated expression of the androgen-regulated antiapoptotic protein c-FLIP in prostate cancer, which is further elevated in CRPC. Repression of c-FLIP induced apoptosis in non-castrate-resistant and CRPC cells and potentiated sensitivity to AR-targeted therapy, indicating that prostate cancer cells require c-FLIP to maintain viability. Consequently, targeting c-FLIP may represent a novel strategy to improve therapeutic response to the novel antiandrogen strategies under clinical development in CRPC. For details, see the article by McCourt and colleagues on page 3822 of this issue.
Clinical Cancer Research

18 (14)

*Clin Cancer Res* 2012;18:3717-3998.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://clincancerres.aacrjournals.org/content/18/14">http://clincancerres.aacrjournals.org/content/18/14</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>